Profile
Yu Xia worked as the Director-Global Quality at Curia Global, Inc. from 2014 to 2016.
Prior to that, he was an Associate Director at Apotex, Inc. from 2011 to 2013.
Currently, he is the Executive Director at Akeso, Inc. from 2019 to 2024.
Additionally, he held a managerial position at Correvio Pharma Corp.
Dr. Xia completed his undergraduate degree at Peking University in 1992.
He later obtained a doctorate degree from the University of Wales (Bangor) in 2001.
Former positions of Yu Xia
| Companies | Position | End |
|---|---|---|
| AKESO, INC. | Director/Board Member | 30/06/2024 |
| ALBANY MOLECULAR RESEARCH, INC. | Corporate Officer/Principal | 01/08/2016 |
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: GenericHealth Technology Manufactures generic medicines | Corporate Officer/Principal | 01/12/2013 |
| CORREVIO PHARMA CORP. | Corporate Officer/Principal | - |
Training of Yu Xia
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Curia Global, Inc.
Curia Global, Inc. BiotechnologyHealth Technology Operates as a global contract research and manufacturing company that provides drug discovery, development & production services | Health Technology |
Correvio Pharma Corp.
Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company for commercializing cardiovascular hospital drugs | Health Technology |
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apotex, Inc.
Apotex, Inc. Pharmaceuticals: GenericHealth Technology Manufactures generic medicines | Health Technology |
University of Wales (Bangor)
University of Wales (Bangor) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akeso, Inc.
Akeso, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapeutic antibodies to patients | Health Technology |
- Stock Market
- Insiders
- Yu Xia
















